Literature DB >> 14749987

Parvovirus B19-related chronic monoarthritis: immunohistochemical detection of virus-positive lymphocytes within the synovial tissue compartment: two reported cases.

Carsten Lennerz1, Henning Madry, Sandra Ehlhardt, Thorsten Venzke, Klaus D Zang, Yasmin Mehraein.   

Abstract

Apart from systemic symptoms of viral infection parvovirus B19, the infectious agent in erythema infectiosum, can lead to mainly self-limited acute and chronic arthropathy. Because mild subclinical features of the disease can be easily overlooked, joint affections might appear as isolated symptoms. We here report two cases of chronic monoarthritic symptoms of unknown origin, where immunohistochemical detection of B19-positive lymphocytic cells in the synovial tissue led to the diagnosis of B19 arthropathy. In conclusion, respective virus diagnostics should be considered even in chronic monosymptomatic arthritic lesions. The pathology of B19 arthropathy seems to be due to direct virus infection of cells within the synovia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14749987     DOI: 10.1007/s10067-003-0800-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  23 in total

1.  Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning.

Authors:  E L Altschuler
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

2.  Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments.

Authors:  S F Cotmore; V C McKie; L J Anderson; C R Astell; P Tattersall
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

Review 3.  Rheumatic manifestations of parvovirus B19 infection.

Authors:  S J Naides
Journal:  Rheum Dis Clin North Am       Date:  1998-05       Impact factor: 2.670

Review 4.  Hematologic and hematopoietic consequences of B19 parvovirus infection.

Authors:  N Young
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

5.  Erythrocyte P antigen: cellular receptor for B19 parvovirus.

Authors:  K E Brown; S M Anderson; N S Young
Journal:  Science       Date:  1993-10-01       Impact factor: 47.728

6.  Parvovirus B19 and erosive polyarthritis.

Authors:  A Tyndall; W Jelk; H H Hirsch
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

7.  Does parvovirus B19 have a role in rheumatoid arthritis?

Authors:  S Nikkari; R Luukkainen; T Möttönen; O Meurman; P Hannonen; M Skurnik; P Toivanen
Journal:  Ann Rheum Dis       Date:  1994-02       Impact factor: 19.103

8.  Human parvovirus B19 as a causative agent for rheumatoid arthritis.

Authors:  Y Takahashi; C Murai; S Shibata; Y Munakata; T Ishii; K Ishii; T Saitoh; T Sawai; K Sugamura; T Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  Human parvovirus arthropathy.

Authors:  D G White; A D Woolf; P P Mortimer; B J Cohen; D R Blake; P A Bacon
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients.

Authors:  I Speyer; F C Breedveld; B A Dijkmans
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

View more
  2 in total

1.  Human endogenous retrovirus W activity in cartilage of osteoarthritis patients.

Authors:  Signy Bendiksen; Inigo Martinez-Zubiavrra; Conny Tümmler; Gunnar Knutsen; Jan Elvenes; Elisabeth Olsen; Randi Olsen; Ugo Moens
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

2.  Extinct type of human parvovirus B19 persists in tonsillar B cells.

Authors:  Lari Pyöriä; Mari Toppinen; Elina Mäntylä; Lea Hedman; Leena-Maija Aaltonen; Maija Vihinen-Ranta; Taru Ilmarinen; Maria Söderlund-Venermo; Klaus Hedman; Maria F Perdomo
Journal:  Nat Commun       Date:  2017-04-04       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.